Antiverse Raises $9.3M Series A and Partners with Cystic Fibrosis Foundation

Antiverse has secured $9.3 million in Series A funding to advance its artificial intelligence driven platform for designing antibodies against difficult disease targets. The Cardiff based techbio company focuses on creating antibody therapies for proteins that have historically been considered hard to drug, including complex membrane receptors.

The funding round was led by Soulmates Ventures with participation from Innovation Investment Capital and other international investors. The new capital will support expansion of the company’s computational antibody design platform, growth of its research team, and development of internal therapeutic programmes.

Alongside the financing, Antiverse announced a research agreement with the Cystic Fibrosis Foundation. The collaboration aims to apply the company’s AI powered antibody discovery technology to identify potential new therapies for cystic fibrosis, a genetic disease that affects the lungs and other organs.

Antiverse combines machine learning models with laboratory validation to design antibodies for challenging targets such as G protein coupled receptors and ion channels. By accelerating the discovery process and improving the probability of identifying effective candidates, the company hopes to unlock treatments for diseases that have previously lacked viable drug options.

The latest investment is expected to strengthen Antiverse’s partnerships with pharmaceutical and biotechnology companies while supporting continued development of next generation antibody therapeutics.